ALX Oncology Holdings (ALXO) Earnings Date & Reports

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

ALXO is expected to report earnings to fall 5.64% to -51 cents per share on May 08

ALX Oncology Holdings ALXO Stock Earnings Reports

Q1'25

Est.

$-0.52

Q4'24

Beat

by $0.12

Q3'24

Beat

by $0.20

Q2'24

Missed

by $0.02

Q1'24

Beat

by $0.11

The last earnings report on March 06 showed earnings per share of -55 cents, beating the estimate of -67 cents. With 1.49M shares outstanding, the current market capitalization sits at 28.92M.

View a ticker or compare two or three

Compare

ALXO